Neurogene Inc. Operating Income
Neurogene Inc. (NGNE) reported Operating Income of -$36.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- Neurogene Inc. operating income (loss) for the quarter ending 2026-06-30 was -$36.67M.
- Neurogene Inc. operating income (loss) for the quarter ending 2026-03-31 was -$33.35M.
- Neurogene Inc. operating income (loss) for the quarter ending 2025-12-31 was -$27.53M.
- Neurogene Inc. operating income (loss) for the quarter ending 2025-09-30 was -$23.80M.
- Neurogene Inc. operating income (loss) for fiscal 2025 was -$103.33M.
- Neurogene Inc. operating income (loss) for fiscal 2024 was -$82.61M.
- Neurogene Inc. operating income (loss) for fiscal 2023 was -$55.58M.
- Neurogene Inc. operating income (loss) for fiscal 2022 was -$56.52M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$36.67M 10-Q · filed 2026-08-11 | -$70.02M 10-Q · filed 2026-08-11 | -$97.55M derived: sum of 3 quarters · filed 2026-08-11 | -$121.35M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$33.35M 10-Q · filed 2026-05-12 | -$60.88M derived: sum of 2 quarters · filed 2026-05-12 | -$84.68M derived: sum of 3 quarters · filed 2026-05-12 | -$110.76M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$27.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$51.33M derived: sum of 2 quarters · filed 2026-03-24 | -$77.41M derived: sum of 3 quarters · filed 2026-08-11 | -$103.33M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | -$23.80M 10-Q · filed 2025-11-13 | -$49.88M derived: sum of 2 quarters · filed 2026-08-11 | -$75.80M 10-Q · filed 2025-11-13 | -$97.31M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$26.08M 10-Q · filed 2026-08-11 | -$52.00M 10-Q · filed 2026-08-11 | -$73.51M derived: sum of 3 quarters · filed 2026-08-11 | -$95.69M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$25.92M 10-Q · filed 2026-05-12 | -$47.43M derived: sum of 2 quarters · filed 2026-05-12 | -$69.61M derived: sum of 3 quarters · filed 2026-05-12 | -$89.75M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$21.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$43.69M derived: sum of 2 quarters · filed 2026-03-24 | -$63.83M derived: sum of 3 quarters · filed 2026-03-24 | -$82.61M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | -$22.18M 10-Q · filed 2025-11-13 | -$42.31M derived: sum of 2 quarters · filed 2025-11-13 | -$61.09M 10-Q · filed 2025-11-13 | -$75.83M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$20.13M 10-Q · filed 2025-08-11 | -$38.91M 10-Q · filed 2025-08-11 | -$53.65M derived: sum of 3 quarters · filed 2025-08-11 | -$68.86M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | -$18.78M 10-Q · filed 2025-05-09 | -$33.51M derived: sum of 2 quarters · filed 2025-05-09 | -$48.73M derived: sum of 3 quarters · filed 2025-05-09 | -$61.33M derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | -$14.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$29.95M derived: sum of 2 quarters · filed 2025-03-24 | -$42.55M derived: sum of 3 quarters · filed 2025-03-24 | -$55.58M 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | -$15.22M 10-Q · filed 2024-11-18 | -$5.57M 10-Q · filed 2023-11-14 | -$27.82M derived: sum of 2 quarters · filed 2024-11-18 | -$40.85M 10-Q · filed 2024-11-18 | -$23.77M 10-Q · filed 2023-11-14 | -$52.52M derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2023-06-30 | -$12.60M 10-Q · filed 2024-08-09 | -$3.07M 10-Q · filed 2023-08-10 | -$25.63M 10-Q · filed 2024-08-09 | -$18.20M 10-Q · filed 2023-08-10 | -$37.30M derived: sum of 3 quarters · filed 2024-08-09 | -$50.91M derived: sum of 4 quarters · filed 2024-08-09 | ||
| 2023-03-31 | -$13.04M 10-Q · filed 2024-05-10 | -$15.13M 10-Q · filed 2023-05-08 | -$24.71M derived: sum of 2 quarters · filed 2024-05-10 | -$38.31M derived: sum of 3 quarters · filed 2024-05-10 | -$54.19M derived: sum of 4 quarters · filed 2024-05-10 | |||
| 2022-12-31 | -$11.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$25.28M derived: sum of 2 quarters · filed 2024-03-18 | -$41.15M derived: sum of 3 quarters · filed 2024-03-18 | -$56.52M 10-K · filed 2024-03-18 | -$59.10M 10-K · filed 2023-03-20 | |||
| 2022-09-30 | -$13.61M 10-Q · filed 2023-11-14 | -$29.48M derived: sum of 2 quarters · filed 2023-11-14 | -$44.85M 10-Q · filed 2023-11-14 | -$60.02M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$15.87M 10-Q · filed 2023-08-10 | -$31.24M 10-Q · filed 2023-08-10 | -$46.41M derived: sum of 3 quarters · filed 2023-08-10 | -$61.86M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$15.37M 10-Q · filed 2023-05-08 | -$30.54M derived: sum of 2 quarters · filed 2023-05-08 | -$45.99M derived: sum of 3 quarters · filed 2023-05-08 | -$61.12M derived: sum of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | -$15.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$30.63M derived: sum of 2 quarters · filed 2023-03-20 | -$45.75M derived: sum of 3 quarters · filed 2023-03-20 | -$60.70M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | -$15.45M 10-Q · filed 2022-11-14 | -$30.58M derived: sum of 2 quarters · filed 2022-11-14 | -$45.52M 10-Q · filed 2022-11-14 | -$58.16M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$15.12M 10-Q · filed 2022-08-09 | -$30.07M 10-Q · filed 2022-08-09 | -$42.71M derived: sum of 3 quarters · filed 2022-08-09 | -$44.96M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$14.95M 10-Q · filed 2022-05-09 | -$27.59M derived: sum of 2 quarters · filed 2022-05-09 | -$29.84M derived: sum of 3 quarters · filed 2022-05-09 | -$39.60M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | -$12.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$14.89M derived: sum of 2 quarters · filed 2022-03-01 | -$24.66M derived: sum of 3 quarters · filed 2022-03-01 | -$33.73M 10-K · filed 2022-03-01 | ||||
| 2020-09-30 | -$2.25M 10-Q · filed 2021-11-04 | -$12.02M derived: sum of 2 quarters · filed 2021-11-04 | -$21.09M 10-Q · filed 2021-11-04 | -$29.45M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | -$9.77M 10-Q · filed 2021-08-05 | -$18.84M 10-Q · filed 2021-08-05 | -$27.20M derived: sum of 3 quarters · filed 2021-08-05 | -$86.71M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | -$9.07M 10-Q · filed 2021-05-12 | -$17.43M derived: sum of 2 quarters · filed 2021-05-12 | -$76.94M derived: sum of 3 quarters · filed 2021-05-12 | -$77.37M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | -$8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$67.87M derived: sum of 2 quarters · filed 2021-03-25 | -$68.30M derived: sum of 3 quarters · filed 2021-03-25 | -$70.96M 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | -$59.52M 10-Q · filed 2020-11-09 | -$59.94M derived: sum of 2 quarters · filed 2020-11-09 | -$62.60M 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | -$428.00K 10-Q · filed 2019-08-01 | -$3.09M 10-Q · filed 2019-08-01 | ||||||
| 2018-12-31 | -$5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$20.50M derived: sum of 2 quarters · filed 2020-03-12 | -$17.81M derived: sum of 3 quarters · filed 2020-03-12 | -$32.62M 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | -$15.20M 10-Q · filed 2019-11-13 | -$12.51M derived: sum of 2 quarters · filed 2019-11-13 | -$27.32M 10-Q · filed 2019-11-13 | |||||
| 2018-06-30 | $2.69M 10-Q · filed 2019-08-01 | -$12.13M 10-Q · filed 2019-08-01 | ||||||
| 2017-12-31 | -$16.53M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$28.60M derived: sum of 2 quarters · filed 2020-03-12 | -$42.60M derived: sum of 3 quarters · filed 2020-03-12 | -$51.12M 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | -$12.07M 10-Q · filed 2018-11-07 | -$26.07M derived: sum of 2 quarters · filed 2018-11-07 | -$34.59M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | -$13.99M 10-Q · filed 2018-08-08 | -$22.52M 10-Q · filed 2018-08-08 | ||||||
| 2016-12-31 | -$37.65M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |